整合组合的2/3阶段的结果是强大的后进展切换和赢家的诅咒
Yu Yang Soon1,2,3, Katrin Sjoquist1,4, Ian C Marschner1
1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
JNCI cancer spectrum
|June 2, 2025
概括
这项研究调整了第二阶段胃癌试验数据,以改变治疗方法和"赢家的诅咒",发现结果与第三阶段一致. 如果评估了错位,将试验数据汇集起来是可行的.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 针对晚期胃癌的INTEGRATE第三期试验与第二期数据进行了合并,引发了对治疗转换和"获胜者诅咒"的担忧.
- 这项研究评估了针对这些潜在错位调整后的第二阶段结果,与第三阶段数据对比.
研究的目的:
- 评估2期和3期晚期胃癌整体生存数据的有效性.
- 评估统计方法调整2期数据治疗转换和"赢家的诅咒"在聚合之前.
主要方法:
- 总体存活率的估计经过调整,使用了等级维护结构失效时间模型 (RPSFTM) 和反向审查权重的概率 (IPCW).
- 一种新的收缩方法减轻了来自"赢家诅咒"的高估,贝叶斯预测方法预测了第三阶段的结果.
- 一项对1万个无的2/3期试验的模拟研究量化了聚合估计中的偏差.
主要成果:
- 调整后的第二阶段估计显示了与未调整后的第三阶段结果 (HR 0.71) 类似的趋势.
- 具体调整后的估计包括HR 0.61 (RPSFTM/收缩),HR 0.59 (RPSFTM/贝叶斯),HR 0.55 (IPCW/收缩) 和HR 0.58 (IPCW/贝叶斯).
- 在零假设和替代假设下,模拟显示了微不足道的偏差 (记录HR为-0.011和0.005).
结论:
- 将第二阶段数据调整为治疗切换和"赢家诅咒"的结果,可以与第三阶段结果相比较.
- 在封闭测试程序下前性地汇集试验数据,如果对错误对齐进行了彻底评估,那么对于第三阶段招聘缺陷是一个可行的策略.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
Comparing the Survival Analysis of Two or More Groups
303
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
303
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
9.3K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
9.3K
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Kaplan-Meier Approach
281
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
281


